Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

1.

Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.

Descotes F, Riche B, Saez S, De Laroche G, Datchary J, Roy P, André J, Bobin JY.

Clin Breast Cancer. 2008 Apr;8(2):168-77. doi: 10.3816/CBC.2008.n.018.

PMID:
18621614
[PubMed - indexed for MEDLINE]
2.

Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.

Jelisavac-Cosic S, Sirotkovic-Skerlev M, Kulic A, Jakic-Razumovic J, Kovac Z, Vrbanec D.

Tumori. 2011 Jul-Aug;97(4):532-9. doi: 10.1700/950.10409.

PMID:
21989445
[PubMed - indexed for MEDLINE]
3.

Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.

Hildenbrand R, Schaaf A, Dorn-Beineke A, Allgayer H, Sütterlin M, Marx A, Stroebel P.

Histol Histopathol. 2009 Jul;24(7):869-77.

PMID:
19475533
[PubMed - indexed for MEDLINE]
4.

Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.

Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.

Cancer. 2004 Aug 1;101(3):486-94.

PMID:
15274061
[PubMed - indexed for MEDLINE]
Free Article
5.

Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).

Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.

Cancer Res. 2002 Aug 15;62(16):4617-22.

PMID:
12183417
[PubMed - indexed for MEDLINE]
Free Article
6.

Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.

Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N.

Clin Cancer Res. 1997 Feb;3(2):233-9.

PMID:
9815678
[PubMed - indexed for MEDLINE]
Free Article
7.

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder ME, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LV, Klijn JG, O'Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA.

J Natl Cancer Inst. 2002 Jan 16;94(2):116-28.

PMID:
11792750
[PubMed - indexed for MEDLINE]
Free Article
8.

Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.

Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW.

J Clin Oncol. 1995 Aug;13(8):2084-93.

PMID:
7636552
[PubMed - indexed for MEDLINE]
9.

Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.

Bouchet C, Ferrero-Poüs M, Hacène K, Becette V, Spyratos F.

Int J Biol Markers. 2003 Jul-Sep;18(3):207-17.

PMID:
14535592
[PubMed - indexed for MEDLINE]
10.

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Hildenbrand R, Schaaf A.

Int J Oncol. 2009 Jan;34(1):15-23.

PMID:
19082473
[PubMed - indexed for MEDLINE]
11.

Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.

Leissner P, Verjat T, Bachelot T, Paye M, Krause A, Puisieux A, Mougin B.

BMC Cancer. 2006 Aug 31;6:216.

PMID:
16945123
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M.

Breast Cancer Res Treat. 1999 Mar;54(2):147-57.

PMID:
10424405
[PubMed - indexed for MEDLINE]
13.

Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.

Grøndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brünner N.

Breast Cancer Res Treat. 1997 Apr;43(2):153-63.

PMID:
9131271
[PubMed - indexed for MEDLINE]
14.

Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M.

Anticancer Res. 1998 May-Jun;18(3C):2173-80.

PMID:
9703780
[PubMed - indexed for MEDLINE]
15.

High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.

Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M.

Cancer Res. 1993 Jun 1;53(11):2513-21.

PMID:
8388317
[PubMed - indexed for MEDLINE]
Free Article
17.

Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.

Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V, Schmitt M.

Thromb Haemost. 2004 Mar;91(3):450-6. Review.

PMID:
14983219
[PubMed - indexed for MEDLINE]
18.

The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.

Meo S, Dittadi R, Peloso L, Gion M.

Int J Biol Markers. 2004 Oct-Dec;19(4):282-8.

PMID:
15646834
[PubMed - indexed for MEDLINE]
19.

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA.

Clin Cancer Res. 2004 Apr 1;10(7):2289-98.

PMID:
15073104
[PubMed - indexed for MEDLINE]
Free Article
20.

Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

De Cremoux P, Grandin L, Diéras V, Savignoni A, Degeorges A, Salmon R, Bollet MA, Reyal F, Sigal-Zafrani B, Vincent-Salomon A, Sastre-Garau X, Magdelénat H, Mignot L, Fourquet A; Breast Cancer Study Group of the Institut Curie.

Anticancer Res. 2009 May;29(5):1475-82.

PMID:
19443353
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk